APTA Share Price Performance
Recent APTA News & Updates
No updates
Aptahem AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- -0.45
- Gross Margin
- 100.00%
- Net Profit Margin
- -235.59%
- Debt/Equity Ratio
- 0%
Aptahem AB (publ) Competitors
About APTA
- Founded
- 2014
- Employees
- 8
- CEO
- WebsiteView website
Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Swedish Market Performance
- 7 Days: -0.3%
- 3 Months: 5.1%
- 1 Year: -2.9%
- Year to Date: 1.1%
The market has stayed flat over the 7 days. As for the longer term, the market has also been flat over the past year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading